In January this year, Covaxin was approved for emergency use in India for people 18 years of age and older.
New Delhi:
Commenting on the Lancet Infectious Diseases study on the effectiveness of COVAXIN (BBV152) for symptomatic RT-PCR, Hyderabad-based Bharat Biotech said that the results compare well with 65.2% efficacy against Delta variation was obtained in a controlled clinical phase 3. trials of COVAXIN were conducted in the general population.
“These results compare well with the 65.2% efficacy against delta variant obtained in COVAXIN phase III controlled clinical trials conducted in the general population. also showed that COVAXIN meets WHO efficacy criteria for COVID-19 vaccine for people with Delta variant,” said Bharat Biotech.
Two doses of COVID-19 vaccine Covaxin (BBV152) are 50% effective against symptomatic COVID-19 disease, according to the first real review of a COVID-19 vaccine published in the journal Infectious Diseases. Lancet.
The study evaluated 2,714 hospital staff at the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15 to May 15, who were symptomatic and underwent RT-PCR testing to detected COVID-19.
“2714 test participants had symptoms still, of which 1,617 tested positive for SARS-CoV-2 and 1,097 tested negative,” the study said.
“The unadjusted effect of two doses of BBV152 on symptomatic confirmed RT-PCR of SARS-CoV-2, with an interval of at least 14 days between taking the second dose and the day of testing, was 53%. After adjustment, the estimated Efficacy was 50%.The adjusted efficacy of the two doses used at least 28 days before the trial was 46% and used at least 42 days before the trial was 57%, “it said.
In January of this year, Covaxin was approved for emergency use in India for people 18 years of age and older. The World Health Organization (WHO) added the vaccine to its list of COVID-19 vaccines for emergency use earlier this month.
(Except for the title, this story has not been edited by NDTV staff and is published from an aggregated feed.)
.
